Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

BACKGROUND: The stimulant prodrug lisdexamfetamine dimesylate (LDX) is an effective and generally well tolerated treatment for the symptoms of attention-deficit/hyperactivity disorder (ADHD). Positive impacts of LDX on health-related quality of life and functional impairment have previously been dem...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:CNS Drugs
Autors principals: Banaschewski, Tobias, Johnson, Mats, Lecendreux, Michel, Zuddas, Alessandro, Adeyi, Ben, Hodgkins, Paul, Squires, Liza A., Coghill, David R.
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2014
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4246127/
https://ncbi.nlm.nih.gov/pubmed/25139785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-014-0193-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars